Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability